Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation...
SABIC Plans Strategic Investment in Rongsheng Petrochemical Subsidiary to Jointly Build a World-Class Benchmark in New Materials
HANGZHOU, China, July 21, 2026 /PRNewswire/ -- A news report from: Shenzhen Panorama Network On July 16, Chinese chemical materials giant Rongsheng Petrochemical announced that the Company and its wholly owned subsidiary Rongsheng New Materials...
Independent Testing Shows Which Business Security Products Actually Hold Up When It Matters
AV-Comparatives publishes its Business Security Test results for March to June 2026, as ransomware and supply-chain attacks continue to disrupt companies of every size INNSBRUCK, Austria, July 15, 2026 /PRNewswire/ -- When Iranian-linked hackers...
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy...
Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a...
Lloyds Energy Ltd Announces Strategic Evaluation of LNG and Regasification Opportunities Across Emerging Energy Markets
DUBAI, UAE, June 23, 2026 /PRNewswire/ -- Lloyds Energy Ltd today announced that it is actively evaluating a range of Liquefied Natural Gas (LNG), Floating Storage and Regasification Unit (FSRU), and downstream gas infrastructure opportunities in...
PMET Advances On-Site Lithium Refining Strategy Through Technology Collaboration MOU with Mitsui and MWCC
MOU to evaluate microwave calcination technology as a key enabling step in PMET's downstream strategy, leveraging the potential use of Quebec's low-cost renewable hydroelectricity to support on-site lithium chemical processing MONTREAL, June 18,...
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast...
Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
Study now open for enrollment at leading academic medical centers CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today...
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
TLX597-Tx is a PSMA[1]-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. OPTIMAL-PSMA[2] initial dosimetry data demonstrate low salivary gland and kidney...